Osaka Medical and Pharmaceutical University · Faculty of Medicine / Graduate School of Medicine

Research keywordsrheumatoid arthritis・JAK inhibitor therapy・rheumatoid arthritis ILD・difficult to treat rheumatoid arthritis・IL 6 blockade・ANSWER cohort・dermatomyositis ILD

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study.2025 · Arthritis research & therapy / 27 / 1
• 関節リウマチにおけるJAK阻害薬治療不応例に対する,他のJAK阻害薬,IL-6阻害薬,TNF阻害薬の3群の有効性に関する比較検討 ANSWERコホートによる解析2025 · 日本リウマチ学会総会・学術集会プログラム・抄録集 / (一社)日本リウマチ学会 / 69回
• Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.2024 · Rheumatology (Oxford, England)
• Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease.2024 · International journal of rheumatic diseases / 27 / 1

• 皮膚筋炎合併間質性肺炎の病態形成機序の解明と疾患制御に向けたバイオマーカーの探索2016

• Official profile
• ORCID